Ebola outbreak in Congo kills 1,900 as virus outpaces health response

The Ebola outbreak in the Democratic Republic of Congo has killed over 1,900 people and infected more than 4,200, making it the second-worst Ebola epidemic in history. The virus, caused by the Bundibugyo strain, is spreading at an unprecedented rate, with health authorities struggling to keep up.

The outbreak is believed to have started in February, months before it was officially declared in May. The World Health Organization (WHO) has warned that the virus is outpacing the response, with WHO Africa director Dr. Mohamed Janabi stating that health authorities are still playing catch-up.

Unlike previous outbreaks, this one is caused by the Bundibugyo strain of the Ebola virus, for which there is no approved vaccine or treatment. The Ervebo vaccine, proven safe and effective against the Zaire strain of Ebola, is not confirmed to work against Bundibugyo. The WHO has recommended a full-scale human trial to test whether Ervebo offers cross-protection.

The current outbreak has a crude case-fatality ratio of 45.5%, meaning nearly half of those infected have died. It has surpassed all previous Ebola outbreaks in terms of speed, including the 2014–2016 West Africa epidemic, which infected 28,000 people and killed over 11,000.

Why this outbreak is different The Bundibugyo strain is genetically distinct from the Zaire strain, which caused the 2014–2016 epidemic. While global preparedness efforts have focused heavily on the Zaire strain—developing rapid diagnostics, vaccines, and treatments—these advances do not automatically apply to Bundibugyo. This gap has left health authorities scrambling to adapt their response.

The global response The WHO’s recommendation for a human trial of the Ervebo vaccine marks a critical step in addressing the outbreak. However, the trial’s outcome remains uncertain, and in the meantime, the virus continues to spread unchecked in some areas. The lack of approved medical countermeasures for Bundibugyo has exposed a major weakness in global epidemic preparedness, despite billions of dollars invested in Ebola response efforts since 2016.

What happens next Health officials are racing to contain the outbreak while awaiting results from the vaccine trial. If Ervebo proves ineffective against Bundibugyo, the world may face an even greater challenge in stopping the virus’s spread. For now, the death toll continues to rise, with no immediate end in sight.